The "e"s have it

Novartis' investigational cancer agent imatinib trade name is changed in U.S. from "Glivec" to "Gleevec" to avoid possible confusion with Pharmacia's diabetes drug Glyset, Novartis says. The name "Glivec" will continue to be used in all other countries where applications have been submitted. The Gleevec NDA was filed Feb. 27 for second-line treatment of chronic myeloid leukemia and is receiving a priority review

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet